- Home
- IQI vs CLLS Comparison
IQI vs CLLS Comparison
Compare IQI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$0.95
Company Overview
Basic Information| Metric | IQI | CLLS |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 460.1M | 394.4M |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | IQI | CLLS |
|---|---|---|
| Price | $8.85 | $0.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.83 |
| AVG Volume (30 Days) | ★ 305.2K | 93.8K |
| Earning Date | 01-01-0001 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.47 | $0.88 |
| 52 Week High | $10.42 | $5.45 |
Technical Indicators
Market Signals| Indicator | IQI | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.23 | 21.98 |
| Support Level | $8.47 | N/A |
| Resistance Level | $9.95 | $2.99 |
| Average True Range (ATR) | 0.16 | 0.09 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 43.21 | 15.95 |
Price Performance
Historical Comparison IQI
CLLS
About IQI Invesco Quality Municipal Income Trust
Invesco Quality Municipal Income Trust is a diversified, closed-end management investment company. Its investment objective is to provide current income which is exempt from federal income tax.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.